Core Viewpoint - 康沣生物-B has entered into a subscription agreement to issue a total of 7.46 million H-shares at a price of HKD 5.36 per share, representing a discount of approximately 17.79% from the closing price on the day of the announcement [2] Group 1 - The net proceeds from the subscription are approximately HKD 39.73 million [2] - 80% of the proceeds will be allocated for the research, production, commercialization, and potential overseas expansion of minimally invasive products related to vascular, respiratory, and oncology interventions [2] - The remaining 20% will be used for the company's general working capital [2]

Core Points - The National Healthcare Security Administration (NHSA) has released a guideline for the pricing of medical services related to the vascular and lymphatic systems, consolidating existing pricing projects into 116 items, with an additional 9 surcharge items and 1 expansion item [1] - The guideline aims to standardize medical service pricing projects to improve pricing accuracy, execution, and evaluation, aligning with clinical diagnosis and treatment needs [1] - Pricing projects are categorized based on vascular differences, with specific pricing for various types of arteries and corresponding stent placement fees, enhancing compatibility of pricing projects [1] - The guideline supports the clinical application of new products and technologies, such as vascular protection devices, which are crucial for preventing serious complications during vascular surgeries [2] - The NHSA will expedite the implementation of the pricing guideline across provinces, ensuring that pricing levels are reasonable and sustainable for patients, healthcare institutions, and insurance funds [2]